Left Menu
Development News Edition

Gilead says drug helped moderately ill coronavirus patients

PTI | Los Angeles | Updated: 02-06-2020 11:36 IST | Created: 02-06-2020 11:00 IST
Gilead says drug helped moderately ill coronavirus patients
Representative Image Image Credit: ANI

A California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19. Gilead Sciences gave few details on Monday but said full results would soon be published in a medical journal.

Remdesivir is the only treatment that's been shown in a rigorous experiment to help fight the coronavirus. A large study led by the National Institutes of Health recently found it could shorten average recovery time from 15 days to 11 days in hospitalized patients with severe disease. The drug is given through an IV and is designed to interfere with an enzyme the virus uses to copy its genetic material. It's approved for treating COVID-19 in Japan and is authorized for emergency use in the United States for certain patients.

The company-led study involved nearly 600 patients who had moderate pneumonia but did not need oxygen support. All were randomly assigned to get five or 10 days of the drug plus standard care, or standard care alone. Patients and their doctors knew who was getting what, which limits the objectivity of the results. By the 11th day in the study, those on five days of remdesivir were 65 percent more likely to improve by at least one on a seven-point scale that included measures such as needing treatment with a breathing machine, Gilead said.

Ten days of treatment did not prove better than standard care alone. There were no deaths among patients on five days of the drug, two among those on 10 days, and four among patients getting standard care alone. Nausea and headache were a little more common among those on the drug.

The study has some limitations, but "there was a control group which does help verify that remdesivir has some benefits," said Dr Radha Rajasingham, an infectious disease specialist at the University of Minnesota Medical Center in Minneapolis who had no role in the work. Since there are limited supplies of the experimental drug, finding benefit from five versus 10 days means more people can be treated, she added.

In a note to investors, Evercore ISI analyst Umer Raffat noted that the study's main goal was changed partway through, from the percentage of patients discharged within two weeks to the scale of improvement after 11 days. "A fair amount of critical data," such as hospital discharge information, has not been disclosed, he wrote.



Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...


Latest News

Russia trying to hack and steal COVID-19 vaccine data, says Britain

Hackers backed by the Russian state are trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world, Britains National Cyber Security Centre NCSC said on Thursday. A co-ordinated st...

Artwork on vehicle body can't ground for denial of registration: High Court

The Punjab and Haryana High Court has ruled that the registration of a vehicle cannot be denied merely due to artwork on its body. The ruling came on a petition filed by Ranjit Malhotra, owner of a multicolour Ambassador Grand Harit-C-1800,...

HC asks Kolhapur jail authority to reconsider parole plea

The Bombay High Court on Thursday directed the authority at the Kolhapur Central Prison in Maharashtra to consider afresh emergency parole pleas of three murder convicts who are serving life sentence. A bench led by Justice S S Shinde was h...

Disengagement process currently underway in eastern Ladakh is specifically aimed at addressing face-off situations:MEA.

Disengagement process currently underway in eastern Ladakh is specifically aimed at addressing face-off situationsMEA....

Give Feedback